Loading
A phase 1 trial of Belzupacap sarotalocan run by Aura Biosciences, active and no longer recruiting.
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer is a phase 1 interventional study registered as NCT05483868 by Aura Biosciences, with 55 participants planned, started 2022-09-26. Conditions recorded: Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma and Urothelial Carcinoma Bladder. Interventions recorded: AU-011, AU-011 in Combination with Medical Laser Adminstration and AU-011 in Combination with Medical Laser Administration.
Shares Aura Biosciences, Belzupacap sarotalocan and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/